Generation of cell-type-specific gene mutations by expressing the sgRNA of the CRISPR system from the RNA polymerase II promoters

Dear Editor,

Recently, the CRISPR/Cas9 system is emerging as a powerful tool for genome editing (Chang et al., 2013; Li et al., 2013; Niu et al., 2014; Shen et al., 2013; Wan et al., 2015; Wang et al., 2013) and genetic screening (Konermann et al., 2015), and holds great promise for biomedical applications in disease modeling and gene therapy by in vivo genome editing (Maddalo et al., 2014; Xue et al., 2014). However, the applications of CRISPR/Cas9 system still face some technical hurdles, one of which is to harness the gene editing in a precisely controlled manner. Of the two-component CRISPR/Cas9 system for genome editing, the Cas9 is a fixed genome-cutting component expressed from the RNA polymerase II (pol II) promoter that can drive tissue-specific gene expression; while the single-guide RNA (sgRNA) is a changeable genome-guiding component expressed from RNA polymerase III (pol III) promoter that usually drives the ubiquitous expression of “housekeeping” genes in all tissues. Therefore, to express the sgRNA in a tissue-specific manner can provide a convenient approach to tissue-specific gene mutations. Here, we reconstructed the sgRNA to enable its expression from the pol II promoters, and further achieved cell-type specific gene mutations via the modified CRISPR/Cas9 system by using cell-type specific pol II promoters-driving sgRNA.

To generate pol II promoter-driving sgRNAs, we constructed a microRNA-shRNA-embedded sgRNA (miRsh-sgRNA) cassette that could express the small RNA from pol II promoter (Wang et al., 2007) into the 3′-untranslational region (UTR) of the DsRed reporter gene (Figs. 1A and S1, and Supplementary Materials), as methods by cis-acting ribozymes (Gao & Zhao, 2014; Nissim et al., 2014) and Cas6/Csv4-based RNA processing (Nissim et al., 2014) have been reported. Notably, the nonsense shRNAs and a reported efficient sgRNA targeting the mouse p53 gene (sgp53) (Xue et al., 2014) was adopted in the construct for a proof-of-concept experiment. The mature sgRNA derived from the miRsh-sgRNA cassette will have additive 7 nucleotides in the 5′-end (Fig. 1A), so we chose a reported optimized sgRNA backbone, the sgRNA5′-end (Fig. 1A), to improve the mutagenesis efficiency (Chen et al., 2013), given that the sgRNAs with mispairing and addition in the 5′-end are still functional (Cong et al., 2013).

To test whether functional sgRNA can be efficiently derived from the pol II promoter-driving miRsh-sgRNA cassette, we transfected mouse embryonic fibroblasts (MEFs) and mouse embryonic stem cells (mESCs) with constitutive EF1α promoter-driving miRsh-sgp53 expression vector and Cas9-P2A-EGFP expression vector. GFP and DsRed double positive cells were sorted by fluorescence-activated cell sorting (FACS) two days after transfection for further analysis (Fig. 1B). The T7EN1 cleavage assay of these cells showed that constitutive EF1α promoter-driving miRsh-sgp53 can guide Cas9 for producing double strand breaks (DSBs) in p53 gene in both MEFs and mESCs (Fig. 1C). To confirm the T7EN1 cleavage results, Sanger sequencing was performed and the result showed that the efficiency of miRsh-sgp53 in MEFs (Fig. 1D) and mESCs (Fig. 1E) was about 50% (6/12) and 57.1% (8/14). These results indicated that the functional sgRNA could be expressed from the pol II promoter-driving miRsh-sgRNA construct for successful gene mutations.

Further, to examine whether the miRsh-sgRNA cassette can produce gene mutation in a cell type-specific manner, we constructed an expression vector using the embryonic stem cell-specific mouse Oct4 gene promoter (mOct4P) to express the miRsh-sgp53 cassette. Two days after transfection of MEFs and mESCs with this vector and the EF1α promoter-driving Cas9-P2A-EGFP vector, GFP and DsRed double-positive mESCs were observed, but only GFP positive MEFs were observed, indicating the cell-type-specific expression of the sgRNA (Fig. 1F). We sorted GFP and DsRed double positive mESCs and GFP positive MEFs by FACS for further analysis. T7EN1 cleavage assay and Sanger sequencing were performed, and p53 gene mutation was only detected in the mESCs but not in the MEFs (Fig. 1G). The result of Sanger sequencing showed that the
potential off targets of the sgp53 (named p53-off-1 to p53-off-41) existing in mouse genome (Table S2). The T7EN1 assay and Sanger sequencing revealed that no potential off target site we tested (Figs. 1I, 1J and S2) was mutated by miRsh
sgp53 in all the examined cells.

In conclusion, we designed a new construct for efficient and visible expression of sgRNAs from the pol II promoters, which therefore can produce cell-type specific mutations. This reconstructed pol II promoter-driving miRsh-sgRNA backbone will make the CRISPR/Cas9 system-mediated genome editing be more controllable and safer for future applications such as in vivo gene therapy.

FOOTNOTES

The authors thank all members of Laboratory of Embryo Biotechnology in College of life science in Northeast Agricultural University and State Key Laboratory of Reproductive Biology in Institute of Zoology in Chinese Academy of Sciences; this study was supported by the grant from the International S&T Cooperation Programme 2013DFG30680, the grant from the “Strategic Priority Research Program” of the Chinese Academy of Sciences XDA01010407, and the grant from the National Basic Research Program (973 Program) (Nos. 2011CB101006 and 2011CB944202). We thank Ting Li, Qing Meng and Hua Qin for their help with fluorescence-activated cell sorting.

Jiaqiang Wang, Xin Li, Yanhua Zhao, Qi Zhou and Zhonghua Liu declare that they have no conflict of interest.

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Jiaqiang Wang1, Xin Li1,2, Yanhua Zhao1, Jingyu Li1, Qi Zhou1,2,3, Zhonghua Liu1,3

1 College of Life Sciences, Northeast Agricultural University, Harbin 150030, China
2 State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China

OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong JX, Xi JX (2013) Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos. Cell Res 23: 465–472

Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, Park J, Blackburn EH, Weissman JS, Qi LS, Huang B (2013)
Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155:1479–1491
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823
Gao Y, Zhao Y (2014) Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPR-mediated genome editing. J Integr Plant Biol 56:343–349
Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J (2013) RNA-programmed genome editing in human cells. eLife 2:e00471
Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583–588
Li W, Teng F, Li T, Zhou Q (2013) Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol 31:684–686
Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Cripta A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516:423–427
Nissim L, Perli SD, Fridkin A, Perez-Pinera P, Lu TK (2014) Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. Mol Cell 54:698–710
Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W, Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T, Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J (2014) Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156:836–843
Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, Zhang X, Zhang P, Huang X (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23:720–723
Wan H, Feng C, Tang F, Yang S, Hu B, Niu Y, Xiang AP, Fang W, Ji W, Li W, Zhao X, Zhou Q (2015) One-step generation of p53 gene biallelic mutant cynomolgus monkey via the CRISPR/Cas system. Cell Res 25:258–261
Wang J, Theunissen TW, Orkin SH (2007) Site-directed, virus-free, and inducible RNAi in embryonic stem cells. Proc Natl Acad Sci USA 104:20850–20855
Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 15:910–918
Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T (2014) CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514:380–384